A Phase Ib Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Summary

The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Glofitamab

  Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)

• Drug
  Tocilizumab

  Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)

• Drug
  Obinutuzumab

  Participants will receive IV obinutuzumab pretreatment

• Drug
  Gemcitabine

  Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)

• Drug
  Oxaliplatin

  Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)

Locations (16)